

FOI REF: 25/798

12th November 2025

**Eastbourne District General Hospital** 

Kings Drive Eastbourne East Sussex BN21 2UD

Tel: 0300 131 4500 Website: www.esht.nhs.uk

## FREEDOM OF INFORMATION ACT

I am responding to your request for information under the Freedom of Information Act. The answers to your specific questions are as follows:

1) How many early-stage (non-metastatic or Stages 1-3) non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:

•	Atezolizumab (Tecentriq)	5
•	Durvalumab (Imfinzi)	1
•	Nivolumab (Opdivo)	0
•	Pembrolizumab (Keytruda)	7
•	Chemotherapy	27

Radiotherapy
 Chemotherapy AND Radiotherapy
 Not applicable
 Not applicable

Please note that East Sussex Healthcare NHS Trust (ESHT) does not deliver Radiotherapy or ChemoRadiotherapy; this is a service delivered by University Hospitals Sussex NHS Foundation Trust. Their details are shown below:

University Hospitals Sussex NHS Foundation Trust

By email: UHSussex.foi@nhs.net

Freedom of Information Office, C/O Company Secretary University Hospitals Sussex NHS Foundation Trust Worthing Hospital Lyndhurst Rd, Worthing BN11 2DH

Osimertinib

2) How many patients has your trust treated in the last 3 months with Pembrolizumab for stage II Melanoma?

ESHT do not treat Melanoma patients; this is a service delivered by University Hospitals Sussex NHS Foundation Trust. Details shown above.

- 3) How many patients has your Trust treated in total in the past 3 months for
  - Stage 2 Non-Small Cell Lung Cancer
    Stage 3 Non-Small Cell Lung Cancer
    7
- 4) How many Stage 2-3 non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:

•	Atezolizumab	1
•	Pembrolizumab monotherapy	3
•	Pembrolizumab with chemotherapy	1
•	Nivolumab	0
•	Osimertinib	0
•	Durvalumab	1
•	Chemotherapy	10

Radiotherapy
 Chemotherapy and Radiotherapy
 Not applicable
 Not applicable

Please note that East Sussex Healthcare NHS Trust (ESHT) does not deliver Radiotherapy or ChemoRadiotherapy; this is a service delivered by University Hospitals Sussex NHS Foundation Trust. Details shown above.

- 5) How many Stage 2-3 non-small cell lung cancer (NSCLC) patients were treated in the past 3 months following surgery with:
  - Chemotherapy 10
  - Radiotherapy
    Chemotherapy + Radiotherapy
    Not applicable
    Not applicable

Please note that East Sussex Healthcare NHS Trust (ESHT) does not deliver Radiotherapy or ChemoRadiotherapy; this is a service delivered by University Hospitals Sussex NHS Foundation Trust. Details shown above.

- 6) How many Stage 2-3 resectable non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:
  - Durvalumab 0

If I can be of any further assistance, please do not hesitate to contact me.

Should you be dissatisfied with the Trust's response to your request, you have the right to request an internal review. Please write to the Freedom of Information Department (<u>eshtr.foi@nhs.net</u>), quoting the above reference, within 40 working days. The Trust is not obliged to accept an internal review after this date.

Should you still be dissatisfied with your FOI request, you have the right of complaint to the Information Commissioner at the following address:

The Information Commissioner's Office Wycliffe House Water Lane Wilmslow Cheshire SK9 5AF

Telephone: 0303 123 1113

Yours sincerely

Freedom of Information Department <a href="mailto:esh-tr.foi@nhs.net">esh-tr.foi@nhs.net</a>